SCHEMBL3498475

SCHEMBL3498475

Cc1c(C(=O)O)oc2cc(-c3ccc(Cl)cc3)ccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.78
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 1/20 0.57
GPR35 Q9HC97 1/20 0.53
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
AURKA O14965 1/20 0.42
TPX2 Q9ULW0 1/20 0.42
KCNH2 Q12809 1/20 0.42
TTR P02766 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DHODH Q02127 1/20 0.40
PTGER4 P35408 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500950 0.88 MCL1 (0.60) MCL1KDM4EALDH1A1GPR35NPC1
SCHEMBL3499014 0.88 MCL1 (0.78) MCL1KDM4EALDH1A1GPR35NPC1
SCHEMBL10293616 0.88 MCL1 (0.63) MCL1KDM4EALDH1A1GPR35NPC1
SCHEMBL1385653 0.88 MCL1 (1.00) MCL1KDM4EALDH1A1GPR35MEN1
SCHEMBL3501203 0.87 MCL1 (0.58) MCL1KDM4EALDH1A1GPR35NPC1
SCHEMBL3501204 0.87 MCL1 (0.58) MCL1KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL3499722 0.82 HIF1A (0.55) MCL1KDM4EALDH1A1NPC1RAB9A
SCHEMBL3500040 0.82 MCL1 (0.53) MCL1KDM4ENPC1RAB9AMEN1
SCHEMBL3498799 0.80 MCL1 (0.51) MCL1KDM4ENPC1RAB9AMEN1
SCHEMBL3499323 0.80 MCL1 (0.50) MCL1KDM4ENPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885KDM4E 2059/4885ALDH1A1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.